A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis

Klinische Forschung - 22.05.2023 - 22.05.2026

Laufend

Projektleitung: Rubbert-Roth Andrea
Mitarbeiter/innen: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis

Klinische Forschung - 14.04.2023 - 14.04.2026

Laufend

Projektleitung: Rubbert-Roth Andrea
Mitarbeiter/innen: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase3 trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo,in combination with a glucocorticoid taper regimen, in patients with po...

Klinische Forschung - 10.03.2023 - 10.03.2026

Laufend

Projektleitung: Rubbert-Roth Andrea
Mitarbeiter/innen: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper...

Klinische Forschung - 01.01.2022 - 01.01.2025

Laufend

Projektleitung: Rubbert-Roth Andrea
Mitarbeiter/innen: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana